Study guide
5.2 Prospective Drug Utilization Review & Patient Medication Profiles
Utah MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Utah Pharmacy Regulatory Framework, Facility Licensing & the PIC
1.1 DOPL, the Utah State Board of Pharmacy & the Sources of Utah Pharmacy Law 1.2 Federal vs. Utah Law: Following the Stricter Standard 1.3 Utah Pharmacy License Classes (A–E) & Facility Licensing 1.4 The Pharmacist-in-Charge (PIC): Duties, Self-Audits & Notifications 1.5 Facility Inspections, Ownership & Location Changes, Closing & Facility Discipline
2 Chapter 2: Pharmacist, Intern & Technician Licensure and Personnel
2.1 Pharmacist Licensure, the NAPLEX & Utah MPJE, and Licensure by Endorsement 2.2 License Renewal, Continuing Education & Reinstatement 2.3 Pharmacy Interns & Preceptors 2.4 Pharmacy Technicians, Technician Trainees & Supportive Personnel
3 Chapter 3: Unlawful & Unprofessional Conduct, Discipline, and Impairment
3.1 Unlawful Conduct, Criminal Penalties, Fines & the Disciplinary Process 3.2 Unprofessional Conduct, the APhA Code of Ethics & Utah's Conscience Law 3.3 Impairment, the Utah Professionals Health Program & Reinstatement
4 Chapter 4: Prescription Issuance, Prescriber Authority & Electronic Prescribing
4.1 Prescriber Scope of Authority in Utah 4.2 Required Prescription Elements, Oral & Faxed Orders, and Alterations 4.3 Mandatory Electronic Prescribing of Controlled Substances (EPCS) in Utah 4.4 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags
5 Chapter 5: Patient Counseling, Prospective DUR, Confidentiality & Records
5.1 Patient Counseling: The Offer, Who May Counsel & Delivered Prescriptions 5.2 Prospective Drug Utilization Review & Patient Medication Profiles 5.3 Confidentiality, HIPAA & Protected Health Information 5.4 Pharmacy Records, Retention Periods & Facility Operating Standards
6 Chapter 6: Expanded Practice: Collaboration, Pharmacist Prescribing & Drug Administration
6.1 Collaborative Pharmacy Practice, Drug Therapy Management & Administration of Drugs 6.2 Self-Administered Hormonal Contraception: Standing Order & Pharmacist Prescribing 6.3 Pharmacist Prescribing Under Utah Code § 58-17b-627: Tobacco Cessation, HIV PrEP/PEP, Fluoride & Epinephrine 6.4 Vaccine Administration: DOPL's Protocol, Delegation, Emergencies & USIIS Reporting
7 Chapter 7: Opioid Overdose Prevention, Emergency Refills & Returned or Donated Drugs
7.1 Naloxone & Opioid-Safety Laws in Utah 7.2 Emergency Refills, Combined Refills & Insulin Continuity 7.3 Returned Drugs, Consumer Disposal & the Charitable Prescription Drug Recycling Program
8 Chapter 8: Controlled Substance Schedules, Registration & Security in Utah
8.1 Controlled Substance Schedules: Federal CSA & Utah-Specific Scheduling 8.2 DEA Registration & Facility Licensing 8.3 Controlled Substance Storage & Physical Security
9 Chapter 9: Dispensing Controlled Substances & the Utah Controlled Substance Database
9.1 Schedule II Prescriptions: 30-Day Window, One-Month Supply, Multiple Prescriptions & the 7-Day Acute Limit 9.2 Schedule II Partial Fills, Emergency Oral Orders & Methadone Emergency Orders 9.3 Schedule III–V Prescriptions: Refill Limits, the 80% Rule & Controlled Substance Transfers 9.4 The Utah Controlled Substance Database (CSD)
10 Chapter 10: Dispensing Standards: Labeling, Substitution, Refills, Packaging, Product Integrity & OTC Products
10.1 Prescription Labels: Utah Minimum Elements, Controlled Substance & Opioid Warnings, and Special Labels 10.2 Drug Product Selection: Generic Equivalents, Therapeutically Similar Drugs & Interchangeable Biologics 10.3 Legend-Drug Prescription Validity, Refills & Transfers 10.4 Poison Prevention Packaging Act (PPPA) & Special Packaging 10.5 Drug Product Conditions That Prohibit Dispensing: Adulterated, Misbranded, Outdated, Recalled & Suspect Products 10.6 Nonprescription Products: OTC Labeling & Packaging, Pseudoephedrine, Iodine, Schedule V & Other Restricted OTC Sales
11 Chapter 11: Acquisition, Inventory, Loss, Distribution & Delivery
11.1 Ordering Schedule II Substances: DEA Form 222 & CSOS 11.2 Controlled Substance Inventories & Utah's Schedule II Perpetual Inventory 11.3 Theft, Significant Loss & Disposal of Controlled Substances 11.4 Drug Acquisition & Distribution, Office-Use Sales, and Delivering Prescriptions to Patients
12 Chapter 12: Compounding Standards, USP Chapters & Hazardous Drugs
12.1 Non-Sterile Compounding & USP <795> Standards 12.2 Sterile Compounding & USP <797> Standards 12.3 Hazardous Drug Handling & USP <800> Standards
13 Chapter 13: Institutional, Central Processing, Remote Dispensing, Specialty Outlets & Automation
13.1 Institutional Practice: Hospitals, Pharmaceutical Administration Facilities & Emergency Drug Kits 13.2 Centralized Prescription Processing, Telepharmacy & Remote Dispensing Pharmacies 13.3 Nuclear Pharmacies, Class E Outlets & Dispensing Medical Practitioners 13.4 Automated Pharmacy Systems, Quality Assurance & Pharmacy Audits
5.2 Prospective Drug Utilization Review & Patient Medication Profiles
Key Takeaways Explain This Topic AI
At the time of dispensing, a Utah pharmacist must review the patient's medication record for inappropriate use, duplication, drug-disease and drug-drug interactions, incorrect dose or duration, drug-allergy interactions, and abuse or misuse (R156-17b-611(2)).
If the review finds a clinically significant problem, the pharmacist must take appropriate steps to avoid or resolve it, including consulting the prescriber (R156-17b-611(3)).
A Utah patient profile must include name, address, phone, date of birth or age, gender, significant history including allergies, and each drug's name, strength, quantity, fill date, and charge (R156-17b-609(2)).
A patient profile must be kept at least one year from the most recent fill or refill (R156-17b-609(1)).
Utah law lets profile information be released only to listed persons, such as the patient, a lawfully authorized drug enforcement officer, the patient's authorized payer, and treating providers (Utah Code § 58-17b-604(4)).
Last updated: September 2026
5.2 Prospective Drug Utilization Review & Patient Medication Profiles
Blueprint item 3.3 covers prospective drug utilization review (DUR), including PMP access. Utah's DUR rule is R156-17b-611 , and the profile rules are § 58-17b-604 and R156-17b-609 . PMP reporting is covered in Section 9.4.
The DUR duty (R156-17b-611(2)–(3))
"For the purpose of promoting therapeutic appropriateness, a pharmacist shall at the time of dispensing a prescription ... review the patient's medication record." The review must at least identify clinically significant:
- inappropriate drug utilization (over- or under-use);
- therapeutic duplication ;
- drug-disease contraindications ;
- drug-drug interactions ;
- incorrect drug dosage or duration of treatment;
- drug-allergy interactions ; and
clinical abuse or misuse .
When the review finds a problem, the pharmacist "shall take appropriate steps to avoid or resolve the problem including consultation with the prescribing practitioner." Failing to do so is unprofessional conduct (R156-17b-502(18)).
Key points:
DUR applies at every dispensing , including refills, because the rule applies whenever a prescription is dispensed.
DUR is a pharmacist (or supervised intern) function. A technician may not perform DUR (R156-17b-601(2)(c)).
Software alerts support DUR but do not replace it. Overriding a serious alert without evaluating it, and without documenting the reason, is inconsistent with the duty to resolve the problem.
- DUR category Example
- Inappropriate utilization A 30-day zolpidem supply requested after 14 days
- Therapeutic duplication Lisinopril and losartan from two different prescribers
- Drug-disease An NSAID for a patient with active peptic ulcer disease
- Drug-drug Clarithromycin for a patient taking high-dose simvastatin
- Dose or duration Ketorolac ordered beyond its 5-day maximum
- Drug-allergy Amoxicillin for a patient with a documented penicillin allergy
Abuse or misuse Concurrent opioid and benzodiazepine from prescribers who don't coordinate, confirmed in the CSD
- Patient medication profiles
- The statute (§ 58-17b-604)
Each pharmacy must establish a medication profile system under DOPL rules.
The pharmacy must maintain a profile for any patient who expresses a desire for that service, and may charge an appropriate professional fee for maintaining it and for copying or providing information to another authorized person.
Release is restricted. A pharmacist, intern, or technician may not release or discuss information in a prescription or profile with anyone except:
- the patient in person , or the patient's legal guardian or designee;
- a lawfully authorized federal, state, or local drug enforcement officer ;
- a third-party payment program the patient has authorized;
a pharmacist, intern, or technician providing pharmacy services to the patient, or a prescribing practitioner treating the patient;
another pharmacist, intern, technician, or prescriber to whom the patient has requested a prescription transfer ; or
the patient's attorney , with written authorization signed before a notary by the patient (or by a parent, guardian, or personal representative, as applicable).
The rule (R156-17b-609)
Requirement Detail
Retention Keep each profile at least one year from the most recent fill or refill . A hospital pharmacy may delete an inpatient profile at discharge if the hospital record keeps the prescriptions.
Minimum contents Patient's full name, address, telephone number, date of birth or age, and gender ; significant patient history, including known allergies and drug reactions ; and a list of prescription drugs obtained at the pharmacy showing name, strength, quantity, fill or refill date, and the charge to the patient; plus any comments relevant to the patient's drug use
Who may enter data A pharmacist, pharmacy intern, pharmacy technician, technician trainee , or DMP designee
The PIC must ensure that "a reasonable effort is made to obtain, record and maintain patient medication records" (R156-17b-603(3)(d)).
DUR and the Controlled Substance Database
The CSD supports DUR for controlled substances and gabapentin. Utah does not require the pharmacist to query it on every fill, but § 58-37f-304(4) requires a dispenser whose review suggests excessive opioid acquisition to reasonably attempt to contact the prescriber . Accessing and reviewing the database in accordance with the chapter carries civil immunity (§ 58-37f-701). See Section 9.4.
Retrospective DUR
Medicaid programs and payers perform retrospective DUR on claims data after dispensing, looking for patterns such as overuse or fraud. On the MPJE, "prospective" means before dispensing, by the pharmacist , and "retrospective" means after dispensing, by a program .
Scenarios
Ciprofloxacin and tizanidine. The combination is contraindicated (CYP1A2 inhibition). The pharmacist should hold the prescription, consult the prescriber about an alternative, and document the intervention.
Patient declines to give allergy history. Utah's rule requires significant history "including known allergies" in the profile, and the PIC must make a reasonable effort to get it. Document the attempt and the patient's refusal, and use professional judgment.
A spouse calls for a list of the patient's medications. Unless the spouse is the patient's legal guardian or designee, § 58-17b-604(4) does not permit release.